Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization

Transplant Immunology

Volumn 28, Issue 2-3, 2013, Pages 138-143

  Wu, G ^a   Chai, N ^a   Kim, Irene ^a   Klein, A S ^a   Jordan, S C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Allosensitization; Anti IL6 receptor monoclonal; Donor specific antibody; IL 6; Skin allograft

Indexed keywords

HLA A2 ANTIBODY; HLA A2 ANTIGEN; HLA ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MMR16 1; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FLOW CYTOMETRY; IMMUNOASSAY; IMMUNOMODULATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SKIN ALLOGRAFT; SPLEEN CELL; TREATMENT DURATION;

EID: 84879799308     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.03.003     Document Type: Article

References (39)

1. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990;4:2860-7.
2. Tanaka T,NarazakiM, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199-219.
3. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009;21:224-30.
4. Muhammad K, Roll P, Seibold T, Kleinert S, Einsele H, Dorner T, et al. Impact of IL-6 receptor inhibition on human memory B-cells in vivo: impaired somatic hypermutation in preswitch memory B-cells and modulation of mutational targeting in memory B-cells. Ann Rheum Dis 2011;70:1507-10.
5. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-52.
6. Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol 2011;4:539-58.
7. Ito H, Hirotani T, Yamamoto M, Ogawa H, Kishimoto T. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol 2002;37(Suppl. 14):56-61.
8. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in seruminterleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
9. Venkiteshwaran A. Tocilizumab. MAbs 2009;1:432-8.
10. Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.Mod Rheumatol 2011;21:215-8.
11. Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009;206:69-78.
12. Cueto-Manzano AM,Morales-Buenrostro LE, González-Espinoza L, González-Tableros N, Martín-del-Campo F, Correa-Rotter R, et al. Markers of inflammation before and after renal transplantation. Transplantation 2005;80:47-51.
13. Booth AJ, Grabauskiene S, Wood SC, Lu G, Burrell BE, Bishop DK. IL-6 promotes cardiac graft rejection mediated by CD4+ cells. J Immunol 2011;187:5764-71.
14. Zhao X, Boenisch O, Yeung M, Mfarrej B, Yang S, Turka LA, et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant 2012;12:90-101.
15. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2499-503.
16. Heidt S, Segundo DS, Chadha R,Wood KJ. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010;15:456-61.
17. Fogal B, Yi T, Wang C, Rao DA, Lebastchi A, Kulkarni S, et al. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J Immunol 2011;187:6268-80.
18. Noguchi D, Daiko W, Takayuki O, Tajima M, Chamoto K, Kitamura H, et al. Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T-cell mediated lethal graft-versus-host reaction against minor histocompatibility antigen. Immunol Lett 2011;136:146-55.
19. Yacoub-Youssef H, Blaes N, Calise D, Thiers JC, Therville N, Benoist H, et al. Interleukin- 6 deficiency fails to prevent chronic rejection after aortic allografts in apolipoprotein E-deficient mice. J Heart Lung Transplant 2009;28:85-92.
20. Wang H, Guan Q, Lan Z, Li S, GeW, ChenH, et al. Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells. Am J Physiol Renal Physiol 2012;302:276-83.
21. Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-11.
22. Yoshida H, Hashizume M, Suzuki M, Mihara M. Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice. Rheumatol Int 2011;31:1445-9.
23. Wu GD, He Y, Chai NN, Toyoda M, Dunn R, Kehry MR, et al. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization. Transpl Immunol 2008;19:178-86.
24. Todo T, Wu G, Chai NN, He Y, Martins G, Gupta A, et al. Anti-CD3{epsilon} induces splenic B220lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization. Int Immunol 2012;24:529-38.
25. Le AX, Bernhard EJ, Holterman MJ, Strub S, Parham P, Lacy E, et al. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J Immunol 1989;142:1366-71.
26. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008;2:75-82.
27. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer-Williams MG. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 2009;21:266-73.
28. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+T cell-B cell collaboration. J Immunol 2007;179:5886-96.
29. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4(Suppl. 3):S233-42.
30. Bauer J, Bauer TM, Kalb T, Taga T, Lengyel G, Hirano T, et al. Regulation of interleukin 6 receptor expression in humanmonocytes andmonocyte-derivedmacrophages. Comparison with the expression in human hepatocytes. J Exp Med 1989;170:1537-49.
31. Zola H, Flego L. Expression of interleukin-6 receptor on blood lymphocytes without in vitro activation. Immunology 1992;76:338-40.
32. Nishida S, Hagihara K, Shima Y, KawaiM, Kuwahara Y, Arimitsu J, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009;68:1235-6.
33. Chong AS, Alegre ML. The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol 2012;12:459-71.
34. Oberbarnscheidt MH, Zecher D, Lakkis FG. The innate immune system in transplantation. Semin Immunol 2011;23:264-72.
35. Horiuchi S, Ampofo W, Koyanagi Y, Yamashita A, Waki M, Matsumoto A, et al. High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy. Immunology 1998;95:360-9.
36. Körholz D, NussbaumP, Pafferath B,Mauz-Körholz C, Hempel L, Burdach S. Activation of protein kinase C induces de novo synthesis of the soluble interleukin-6 receptor in human B cells. Scand J Immunol 1994;40:515-20.
37. Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol 2010;185: 5512-21.
38. Wognum AW, van Gils FC, Wagemaker G. Flow cytometric detection of receptors for interleukin-6 on bone marrow and peripheral blood cells of humans and rhesus monkeys. Blood 1993;81:2036-43.
39. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Chron's disease and experimental colitis in vivo. Nat Med 2000;6:583-8.